StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
22
This year
1
Publishing Date
2024 - 01 - 09
1
2023 - 08 - 28
1
2023 - 07 - 21
1
2023 - 06 - 06
2
2023 - 04 - 26
2
2022 - 03 - 24
1
2021 - 11 - 22
1
2021 - 11 - 15
1
2021 - 10 - 28
1
2021 - 10 - 04
2
2021 - 09 - 14
1
2021 - 07 - 01
1
2021 - 05 - 25
1
2021 - 05 - 24
1
2021 - 05 - 18
1
2021 - 04 - 22
1
2021 - 04 - 13
2
2020 - 12 - 10
1
Sector
Health technology
22
Tags
Alliances
1
Approval
2
Brain metastases
1
Cancer
17
Cell
4
China
3
Clinical-trials-phase-ii
2
Clinical-trials-phase-iii
4
Collaboration
2
Decades
1
Dmc recommendations
1
Ef-14
1
Enroll
5
Europe
2
Events
1
Extension
2
Favorable
1
Fda
2
Fda approval
1
Fda ide
1
Fda-approvals
1
Glioblastoma
4
Gog-3029
1
Ide approval
1
Liver
1
Lung
4
Lung cancer
6
Meeting
2
N/a
10
Ovarian cancer
1
Pancreas
1
Pancreatic
2
Phase 2
4
Phase 3
7
Positive
1
Presentation
2
Radiation therapy
1
Research
1
Results
4
Therapy
6
Topline
1
Train
1
Treatment
3
Trial
22
Tumor
2
Update
1
Entities
4d molecular therapeutics inc
24
Abb ltd
72
Abbvie inc.
62
Actinium pharmaceuticals, inc.
28
Aldeyra therapeutics, inc.
38
Alnylam pharmaceuticals, inc.
38
Alterity therapeutics limited
26
Altra industrial motion corp.
23
Amgen inc.
25
Anavex life sciences corp.
24
Arcutis biotherapeutics, inc.
29
Arrival
26
Arrowhead pharmaceuticals, inc.
24
Astellas pharma inc
26
Astrazeneca plc
64
Beigene, ltd.
35
Biogen inc.
23
Biovie inc.
28
Bioxcel therapeutics, inc.
27
Bristol-myers squibb company
73
Clearside biomedical, inc.
24
Clene inc
25
Cnh industrial n.v.
69
Cybin inc
26
Cytokinetics, incorporated
29
Dynavax technologies corporation
28
Eli lilly and company
161
Enlivex therapeutics ltd.
26
Exelixis, inc.
28
Fortress biotech, inc.
41
Gates industrial corporation plc
25
Gilead sciences, inc.
48
Global industrial co
38
Honeywell international inc.
53
Horizon therapeutics public limited company
46
I-mab
34
Icon plc
43
Immix biopharma, inc.
26
Immutep limited
34
Incyte corporation
49
Johnson & johnson
203
Medtronic plc
25
Merck & company, inc.
72
Moleculin biotech, inc.
34
Novartis ag
34
Novo nordisk a/s
42
Ocugen, inc.
27
Orange
91
Pds biotechnology corporation
25
Pfizer, inc.
61
Plus therapeutics, inc.
35
Regeneron pharmaceuticals, inc.
44
Regenxbio inc.
29
Sanofi
311
Sellas life sciences group, inc.
24
Sorrento therapeutics, inc.
38
Stag industrial, inc.
32
Takeda pharmaceutical company limited
56
Tg therapeutics, inc.
27
Thermo fisher scientific inc
48
Symbols
NVCR
22
ZLAB
6
Exchanges
Nasdaq
22
Crawled Date
2024 - 01 - 09
1
2023 - 08 - 28
1
2023 - 07 - 21
1
2023 - 06 - 06
2
2023 - 04 - 26
2
2022 - 03 - 24
1
2021 - 11 - 22
1
2021 - 11 - 15
1
2021 - 10 - 28
1
2021 - 10 - 04
2
2021 - 09 - 14
1
2021 - 07 - 01
1
2021 - 05 - 25
1
2021 - 05 - 24
1
2021 - 05 - 18
1
2021 - 04 - 22
1
2021 - 04 - 13
2
2020 - 12 - 10
1
Crawled Time
11:00
1
12:00
9
12:30
1
13:00
2
13:20
1
13:30
1
14:00
2
14:30
1
15:00
3
20:00
1
Source
www.biospace.com
12
www.globenewswire.com
5
www.novocure.com
5
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
trial
entities :
Novocure limited
save search
Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma
Published:
2024-01-09
(Crawled : 13:30)
- biospace.com/
NVCR
|
$12.175
1.0%
210K
|
Health Technology
|
-18.88%
|
O:
1.25%
H:
4.12%
C:
-2.06%
trial
glioblastoma
Novocure Provides Update on Phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 Trial Evaluating Tumor Treating Fields Therapy in Platinum-resistant Ovarian Cancer
Published:
2023-08-28
(Crawled : 14:30)
- biospace.com/
NVCR
|
$12.175
1.0%
210K
|
Health Technology
|
-59.52%
|
O:
-33.69%
H:
6.18%
C:
-5.75%
gog-3029
update
cancer
tumor
trial
therapy
Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer
Published:
2023-07-21
(Crawled : 13:20)
- biospace.com/
NVCR
|
$12.175
1.0%
210K
|
Health Technology
|
-68.78%
|
O:
-0.75%
H:
2.79%
C:
1.59%
favorable
cancer
pancreatic
tumor
trial
therapy
LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Published:
2023-06-06
(Crawled : 15:00)
- biospace.com/
NVCR
|
$12.175
1.0%
210K
|
Health Technology
|
-85.4%
|
O:
-9.53%
H:
0.68%
C:
-37.04%
lung
cancer
cell
extension
trial
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Published:
2023-06-06
(Crawled : 12:00)
- globenewswire.com
ZLAB
|
$15.61
3.24%
190K
|
Health Technology
|
-57.32%
|
O:
-2.43%
H:
0.67%
C:
-2.98%
NVCR
|
$12.175
1.0%
210K
|
Health Technology
|
-85.4%
|
O:
-9.53%
H:
0.68%
C:
-37.04%
lung
cancer
cell
extension
trial
Novocure Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Published:
2023-04-26
(Crawled : 15:00)
- biospace.com/
NVCR
|
$12.175
1.0%
210K
|
Health Technology
|
-80.23%
|
O:
0.26%
H:
7.67%
C:
4.81%
lung
presentation
cancer
cell
meeting
trial
results
Zai Lab Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Published:
2023-04-26
(Crawled : 15:00)
- globenewswire.com
ZLAB
|
$15.61
3.24%
190K
|
Health Technology
|
-56.48%
|
O:
2.65%
H:
1.91%
C:
-2.78%
NVCR
|
$12.175
1.0%
210K
|
Health Technology
|
-80.23%
|
O:
0.26%
H:
7.67%
C:
4.81%
lung
presentation
cancer
cell
meeting
trial
results
Updated 2-THE-TOP Data Suggest Improvements in Progression-Free Survival, Overall Survival Compared to Matched-Control Patients from EF-14 Trial
Published:
2022-03-24
(Crawled : 20:00)
- novocure.com
NVCR
|
$12.175
1.0%
210K
|
Health Technology
|
-85.33%
|
O:
0.41%
H:
0.27%
C:
-2.87%
ef-14
trial
Novocure Announces Last Patient Enrolled in Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-small Cell Lung Cancer
Published:
2021-11-22
(Crawled : 12:30)
- novocure.com
NVCR
|
$12.175
1.0%
210K
|
Health Technology
|
-88.94%
|
O:
-4.3%
H:
0.0%
C:
0.0%
lung cancer
cancer
phase 3
trial
enroll
2-THE-TOP Phase 2 Trial Reports Positive Top-Line Results in Newly Diagnosed Glioblastoma
Published:
2021-11-15
(Crawled : 13:00)
- biospace.com/
NVCR
|
$12.175
1.0%
210K
|
Health Technology
|
-89.31%
|
O:
3.0%
H:
0.39%
C:
-3.17%
phase 2
positive
results
trial
topline
glioblastoma
Novocure Announces Last Patient Enrolled in Phase 3 Pivotal INNOVATE-3 Trial of Tumor Treating Fields in Ovarian Cancer
Published:
2021-10-28
(Crawled : 12:00)
- biospace.com/
NVCR
|
$12.175
1.0%
210K
|
Health Technology
|
-89.12%
|
O:
-4.1%
H:
0.0%
C:
-4.24%
cancer
phase 3
ovarian cancer
trial
enroll
Zai Lab and Novocure Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China
Published:
2021-10-04
(Crawled : 12:00)
- globenewswire.com
ZLAB
|
$15.61
3.24%
190K
|
Health Technology
|
-85.86%
|
O:
-4.58%
H:
2.65%
C:
0.49%
NVCR
|
$12.175
1.0%
210K
|
Health Technology
|
-89.74%
|
O:
-1.34%
H:
0.07%
C:
-5.6%
treatment
phase 2
china
therapy
cancer
trial
enroll
Novocure and Zai Lab Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China
Published:
2021-10-04
(Crawled : 12:00)
- biospace.com/
ZLAB
|
$15.61
3.24%
190K
|
Health Technology
|
-85.86%
|
O:
-4.58%
H:
2.65%
C:
0.49%
NVCR
|
$12.175
1.0%
210K
|
Health Technology
|
-89.74%
|
O:
-1.34%
H:
0.07%
C:
-5.6%
treatment
phase 2
china
therapy
cancer
trial
enroll
Novocure Announces Clinical Trial Collaboration with Roche to Evaluate Tumor Treating Fields as Part of a Novel Combination for the First-line Treatment of Metastatic Pancreatic Cancer
Published:
2021-09-14
(Crawled : 11:00)
- novocure.com
NVCR
|
$12.175
1.0%
210K
|
Health Technology
|
-90.7%
|
O:
1.68%
H:
0.14%
C:
-4.27%
treatment
collaboration
cancer
trial
pancreatic
pancreas
Novocure Presents Final Safety and Efficacy Results from its Phase 2 Pilot HEPANOVA Trial in Liver Cancer
Published:
2021-07-01
(Crawled : 12:00)
- biospace.com/
NVCR
|
$12.175
1.0%
210K
|
Health Technology
|
-94.57%
|
O:
-6.82%
H:
0.38%
C:
-8.21%
phase 2
results
cancer
liver
trial
Novocure Announces Clinical Trial Collaboration with GT Medical Technologies to Evaluate Tumor Treating Fields Together with GammaTile® Therapy in Recurrent Glioblastoma
Published:
2021-05-25
(Crawled : 12:00)
- novocure.com
NVCR
|
$12.175
1.0%
210K
|
Health Technology
|
-93.49%
|
O:
-0.07%
H:
2.41%
C:
1.52%
therapy
collaboration
trial
glioblastoma
Zai Lab Announces First Patient Treated in Greater China in METIS Phase 3 Pivotal Trial of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer
Published:
2021-05-24
(Crawled : 14:00)
- globenewswire.com
ZLAB
|
$15.61
3.24%
190K
|
Health Technology
|
-90.82%
|
O:
-1.44%
H:
6.49%
C:
0.17%
NVCR
|
$12.175
1.0%
210K
|
Health Technology
|
-93.34%
|
O:
0.54%
H:
3.92%
C:
1.88%
lung cancer
china
cancer
phase 3
trial
train
brain metastases
Novocure Announces FDA Approval of IDE Supplement for Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer
Published:
2021-05-18
(Crawled : 12:00)
- biospace.com/
NVCR
|
$12.175
1.0%
210K
|
Health Technology
|
-93.11%
|
O:
2.67%
H:
6.29%
C:
0.34%
fda
lung cancer
fda approval
cancer
phase 3
trial
approval
Novocure Announces FDA IDE Approval and Steering Committee for KEYNOTE-B36 Trial Evaluating Tumor Treating Fields Together with Pembrolizumab in Non-Small Cell Lung Cancer
Published:
2021-04-22
(Crawled : 13:00)
- novocure.com
NVCR
|
$12.175
1.0%
210K
|
Health Technology
|
-93.99%
|
O:
-0.08%
H:
2.65%
C:
-0.61%
fda
lung cancer
ide approval
cancer
trial
approval
fda ide
Novocure Announces Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer
Published:
2021-04-13
(Crawled : 12:00)
- biospace.com/
NVCR
|
$12.175
1.0%
210K
|
Health Technology
|
-90.86%
|
O:
50.14%
H:
10.14%
C:
-0.34%
lung cancer
cancer
phase 3
trial
dmc recommendations
decades
← Previous
1
2
Next →
Gainers vs Losers
55%
45%
Top 10 Gainers
CSSE
4
|
$0.3499
129.74%
150M
|
Consumer Services
CZOO
|
$11.04
121.24%
9.6M
|
BOF
|
$2.05
75.21%
78M
|
AMST
|
$3.2
60.0%
63M
|
Technology Services
LICN
|
$0.8592
53.43%
13M
|
WIMI
|
$1.05
44.75%
13M
|
Technology Services
TROO
|
$1.51
38.53%
5.6M
|
Manufacturing
MULN
|
News
|
$3.7
35.53%
6.4M
|
Information
RILY
|
$27.91
28.5%
8.9M
|
Finance
WHLM
|
$6.43
26.58%
580K
|
Commercial Services
Your saved searches
Save your searches and get alerts when important news are released.